Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitrendipine + hydrochlorothiazide is a fixed-dose combination of two antihypertensive agents used for the treatment of hypertension. Nitrendipine is a dihydropyridine calcium channel blocker that acts as a peripheral vasodilator by inhibiting the influx of extracellular calcium across myocardial and vascular smooth muscle cell membranes, leading to decreased vascular resistance and blood pressure[5][8]. Hydrochlorothiazide is a thiazide diuretic that reduces blood pressure by increasing renal excretion of sodium and water, thereby decreasing plasma volume[2][3][4]. The combination provides additive antihypertensive effects compared to either agent alone, making it effective in patients who require more than one medication to achieve blood pressure control[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nitrendipine + hydrochlorothiazide.